defactinib
defactinib: developed by 1 company · 16 clinical trials tracked.
defactinib evidence translation
What we can confirm
16 tracked trials
What it means
What to watch
Prepared research question
How could defactinib → VSTM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Verastem, Inc. (VSTM) Low Grade Serous Ovarian Cancer | Phase 3 |
Clinical Trials (16)showing 10 most recent
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Primary endpoint: Safety and adverse events (AEs).
Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Primary endpoint: Progression-free survival (PFS) - Experimental Arm Only
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Primary endpoint: Safety and adverse events (AEs)
A Phase 1/2 Trial of the Doublet Combination of Avutometinib and Defactinib and as a Triplet in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform
Primary endpoint: Phase 1b - To evaluate the safety and tolerability of investigational agent in patients with malignant brain tumours
A Phase II Trial of Avutometinib in Combination With Defactinib in Metastatic Diffuse Gastric Cancer
Primary endpoint: Progression-free survival (PFS) Rate
Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting
Primary endpoint: objective response rate
Phase 1b/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Primary endpoint: Response rate defined as Partial Response (PR) + Complete Response (CR) using Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria of all measurable target lesions present at the time of enrollment on trial.
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
Primary endpoint: Progression Free Survival (PFS) per blinded independent central review (BICR)
Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
Primary endpoint: overall response rate (ORR) cohort A
A Single-Dose Study of Orally Administrated Defactinib or VS-6766 in Patients With Glioblastoma
Primary endpoint: Concentration of defactinib that accumulates in the glioblastoma (GBM) and brain around tumor
Frequently asked questions
Who is developing defactinib?
defactinib is being developed by Verastem, Inc..
How many clinical trials involve defactinib?
BioSniper tracks 16 clinical trials involving defactinib.